secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annovis Bio, Inc. (ANVS)
CIK:        0001477845
Form:       8-K
Filed at:   2026-10-19T23:49:30+00:00
Accession:  0001104659-26-116995
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Annovis Bio corrects proxy typo, restates Ernst & Young audit fees at $415,000 for 2025
--------------------------------------------------------------------------------

- Correction fixes a typographical error in the audit-fee disclosure in the proxy statement for the annual meeting held June 17, 2026.
- 2025 Ernst & Young fees: audit $415,000, audit-related $100,000, total $515,000.
- 2024 Ernst & Young fees: audit $375,000, audit-related $107,045, total $482,045.
- No tax fees or all-other fees were reported in either 2025 or 2024; no change of auditor disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1477845/000110465926116995/0001104659-26-116995-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1477845/000110465926116995/tm2627875d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-116995

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer